TransThera's resistant biliary cancer drug cleared in China
TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
Newsletters and Deep Dive digital magazine
TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
Recent biotech financings are headed by LifeMine's $263m for a transplant drug, with Expedition, Ratio, Vedanta, and Mironid also in on the action.
NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks